[go: up one dir, main page]

BR0016172A - 4-piridinil-n-acil-l-fenilalaninas - Google Patents

4-piridinil-n-acil-l-fenilalaninas

Info

Publication number
BR0016172A
BR0016172A BR0016172-1A BR0016172A BR0016172A BR 0016172 A BR0016172 A BR 0016172A BR 0016172 A BR0016172 A BR 0016172A BR 0016172 A BR0016172 A BR 0016172A
Authority
BR
Brazil
Prior art keywords
pyridinyl
acyl
phenylalanines
vcam
binding
Prior art date
Application number
BR0016172-1A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BR0016172A publication Critical patent/BR0016172A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

"4-PIRIDINIL-N-ACIL-L-FENILALANINAS". Compostos apresentando a fórmula (1) são revelados em que R~ 1~ a R~ 7~ são tal com definidos no presente documento e os quais tem atividade como inibidores de ligação entre VCAM-1 e células que expressam VLA-4 e, portanto, são úteis no tratamento de doenças cujos sintomas e/ou danos estão relacionados à ligação de VCAM-1 às células que expressam VLA-4, tal como doenças inflamatórias crónicas.
BR0016172-1A 1999-12-06 2000-11-29 4-piridinil-n-acil-l-fenilalaninas BR0016172A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16909099P 1999-12-06 1999-12-06
PCT/EP2000/011979 WO2001042215A1 (en) 1999-12-06 2000-11-29 4-pyridinyl-n-acyl-l-phenylalanines

Publications (1)

Publication Number Publication Date
BR0016172A true BR0016172A (pt) 2002-08-20

Family

ID=22614226

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0016172-1A BR0016172A (pt) 1999-12-06 2000-11-29 4-piridinil-n-acil-l-fenilalaninas

Country Status (34)

Country Link
EP (1) EP1244625B1 (pt)
JP (2) JP2003516392A (pt)
KR (1) KR100492111B1 (pt)
CN (1) CN1196682C (pt)
AR (1) AR031083A1 (pt)
AT (1) ATE297895T1 (pt)
AU (1) AU779063B2 (pt)
BR (1) BR0016172A (pt)
CA (1) CA2392566A1 (pt)
CO (1) CO5080771A1 (pt)
CZ (1) CZ20022352A3 (pt)
DE (1) DE60020883T2 (pt)
DK (1) DK1244625T3 (pt)
ES (1) ES2243335T3 (pt)
GC (1) GC0000214A (pt)
HK (1) HK1053470A1 (pt)
HR (1) HRP20020467A2 (pt)
HU (1) HUP0203735A3 (pt)
IL (2) IL149622A0 (pt)
JO (1) JO2281B1 (pt)
MA (1) MA26849A1 (pt)
MX (1) MXPA02005240A (pt)
MY (1) MY128003A (pt)
NO (1) NO322910B1 (pt)
NZ (1) NZ518888A (pt)
PE (1) PE20010960A1 (pt)
PL (1) PL364814A1 (pt)
PT (1) PT1244625E (pt)
RU (1) RU2270193C2 (pt)
TW (1) TWI276629B (pt)
UY (1) UY26470A1 (pt)
WO (1) WO2001042215A1 (pt)
YU (1) YU40502A (pt)
ZA (1) ZA200203762B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
DE60143984D1 (de) 2000-08-18 2011-03-17 Ajinomoto Kk Neue phenylalanin-derivate
WO2002028830A1 (fr) 2000-09-29 2002-04-11 Ajinomoto Co.,Inc. Nouveaux derives de phenylalanine
EP1454898A4 (en) 2001-12-13 2006-12-13 Ajinomoto Kk NEW PHENYL ALANIDE DERIVATIVES
US7998986B2 (en) 2001-12-21 2011-08-16 Exelixis Patent Company Llc Modulators of LXR
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
CN1917881B (zh) 2003-12-22 2014-11-26 味之素株式会社 新型苯基丙氨酸衍生物
US7618981B2 (en) * 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
ATE430761T1 (de) * 2004-08-16 2009-05-15 Merck & Co Inc Vla-4-antagonisten
JP4784224B2 (ja) 2004-09-24 2011-10-05 味の素株式会社 糖鎖転移方法および糖鎖転移酵素
JP2009531304A (ja) * 2006-02-28 2009-09-03 エラン ファーマシューティカルズ，インコーポレイテッド α−４阻害剤化合物を用いて炎症性疾患および自己免疫疾患を治療する方法
AR060901A1 (es) * 2006-05-12 2008-07-23 Jerini Ag Compuestos heterociclicos para la inhibicion de integrinas y uso de estos
WO2008103378A2 (en) 2007-02-20 2008-08-28 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
BRPI0911652A2 (pt) 2008-04-11 2015-08-04 Merrimack Pharmaceuticals Inc Ligantes de albumina sérica humana e seus conjugados
ES2494465T3 (es) * 2009-07-23 2014-09-15 Bayer Cropscience Ag Procedimiento para la preparación de alcoxienonas y enaminocetonas
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
RU2624731C2 (ru) * 2012-01-27 2017-07-06 Ф. Хоффманн-Ля Рош Аг Конъюгаты антагонистов интегрина для нацеленной доставки к клеткам, экспрессирующим vla-4
JP6573604B2 (ja) * 2013-06-11 2019-09-11 セルジーン インターナショナル ツー エスエーアールエル 新規なｇｌｐ−１レセプターモジュレーター
EA036432B1 (ru) 2016-02-05 2020-11-10 Эа Фарма Ко., Лтд. Производные сульфонамида и содержащие их фармацевтические композиции
JP7214882B2 (ja) 2018-10-30 2023-01-30 ギリアード サイエンシーズ， インコーポレイテッド アルファ４ベータ７インテグリン阻害剤としてのイミダゾピリジン誘導体
US11179383B2 (en) 2018-10-30 2021-11-23 Gilead Sciences, Inc. Compounds for inhibition of α4β7 integrin
JP7189368B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４ベータ７インテグリンの阻害のための化合物
AU2019373240B2 (en) 2018-10-30 2023-04-20 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
KR20220047323A (ko) 2019-08-14 2022-04-15 길리애드 사이언시즈, 인코포레이티드 알파 4 베타 7 인테그린의 저해용 화합물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002512625A (ja) * 1997-05-29 2002-04-23 メルク エンド カンパニー インコーポレーテッド 細胞接着阻害薬としての複素環アミド化合物
AU726585B2 (en) * 1997-05-29 2000-11-09 Merck & Co., Inc. Biarylalkanoic acids as cell adhesion inhibitors
US6197794B1 (en) * 1998-01-08 2001-03-06 Celltech Therapeutics Limited Phenylalanine derivatives
MY153569A (en) * 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
US6329372B1 (en) * 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
ES2226413T3 (es) * 1998-02-26 2005-03-16 Celltech Therapeutics Limited Derivados de fenilalanina como inhibidores de alfa-4 integrinas.
GB9811159D0 (en) * 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
ES2220140T3 (es) * 1998-12-22 2004-12-01 Tanabe Seiyaku Co., Ltd. Inhibidores de la adhesion mediada de celulas por alfa 4 beta 1 (a4b1).
DE60021251D1 (de) * 1999-01-22 2005-08-18 Elan Pharm Inc Multizyklische verbindungen zur hemmung der durch vla-4 vermittelten leukozytenadhäsion

Also Published As

Publication number Publication date
ATE297895T1 (de) 2005-07-15
RU2270193C2 (ru) 2006-02-20
GC0000214A (en) 2006-03-29
MY128003A (en) 2007-01-31
NZ518888A (en) 2004-02-27
AU779063B2 (en) 2005-01-06
AR031083A1 (es) 2003-09-10
CN1402709A (zh) 2003-03-12
CO5080771A1 (es) 2001-09-25
UY26470A1 (es) 2001-05-31
NO20022650L (no) 2002-06-05
PT1244625E (pt) 2005-09-30
HK1053470A1 (en) 2003-10-24
CN1196682C (zh) 2005-04-13
EP1244625B1 (en) 2005-06-15
WO2001042215A1 (en) 2001-06-14
DE60020883T2 (de) 2006-03-23
HUP0203735A3 (en) 2005-03-29
EP1244625A1 (en) 2002-10-02
HUP0203735A2 (hu) 2003-03-28
IL149622A0 (en) 2002-11-10
PE20010960A1 (es) 2001-09-22
JO2281B1 (en) 2005-09-12
PL364814A1 (en) 2004-12-13
MXPA02005240A (es) 2002-11-07
AU2163901A (en) 2001-06-18
NO20022650D0 (no) 2002-06-05
IL149622A (en) 2006-12-10
ZA200203762B (en) 2004-01-28
JP2003516392A (ja) 2003-05-13
HRP20020467A2 (en) 2004-04-30
ES2243335T3 (es) 2005-12-01
YU40502A (sh) 2005-03-15
CA2392566A1 (en) 2001-06-14
CZ20022352A3 (cs) 2003-05-14
KR100492111B1 (ko) 2005-06-01
NO322910B1 (no) 2006-12-18
TWI276629B (en) 2007-03-21
JP2008094842A (ja) 2008-04-24
KR20020060256A (ko) 2002-07-16
DK1244625T3 (da) 2005-10-10
MA26849A1 (fr) 2004-12-20
DE60020883D1 (de) 2005-07-21

Similar Documents

Publication Publication Date Title
BR0016172A (pt) 4-piridinil-n-acil-l-fenilalaninas
BR0016195A (pt) 4-pirimidinil-n-acil-l-fenilalaninas
DE69824183D1 (de) N-alkanoylphenylalaninderivate
BR9811988A (pt) Derivados de n-alcanoilfenilalanina
BR0111206A (pt) Derivados de arilmetilamina para uso como inibidores de triptase
BR0309556A (pt) Inibidores de metaloproteinase pirimidina-2,4,6-triona
BR0010076A (pt) Inibidores de renina
BR0010080A (pt) Inibidores de renina
BR9810450A (pt) Derivados de ácido barbitúrico com atividade antimetastática e antitumor
BRPI0517999A (pt) derivados de tetraidropirano como antidiabéticos
BR0011291A (pt) Derivados de ácido hidroxâmico como inibidores de metaloprotease de matriz
NO20014240L (no) C16-umettede FP-selektive prostaglandinanaloger
TR200103004T2 (tr) Pirolidinkarbonilamino siklik disülfitler.
BR0008368A (pt) Derivados fenilalaninol
BR0015404A (pt) Compostos relacionados com ácido 15-hidroxieicosatetraenóico e métodos de uso
DK1244643T3 (da) Tryptaseinhibitorer
DK1244614T3 (da) Tryptase-inhibitorer
BRPI0511323A (pt) tetraidroisoquinolinas substituìdas usadas na forma de inibidores de mmp, método para a produção e uso das mesmas na forma de drágeas
BRPI0417140A (pt) derivados quinolina ácidos e seu uso na prevenção e/ou tratamento de patologias relacionadas com hiperglicemia
ECSP982634A (es) Derivados de n- aroilofenil alanina

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8, 10(VIII), 11, 13, 24 E 25 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.